Purchase Order 75F40119P10348
- Not listed
- This federal contract award was issued by the Food and Drug Administration (FDA), a civilian agency within the Department of Health and Human Services (HHS), to Sartorius Stedim North America Inc., a subsidiary of the German company Sartorius Aktiengesellschaft. The $89,489.60 Firm Fixed Price Purchase Order is for the supply of bioreactor parts and accessories. The contract does not have a set-aside designation. Sartorius Stedim North America Inc. is a leading provider of laboratory...
- This federal contract was awarded by the Department of Health and Human Services Food and Drug Administration to Sartorius Stedim North America Inc., a division of the German company Sartorius Aktiengesellschaft. The $198,816.00 fixed-price contract is for maintenance on a Sartorius Biostat B-DCU II parallel bioreactor system. The contract has no set-aside designation and was awarded on December 20, 2018, with a completion date of January 1, 2022. Sartorius Stedim North America Inc. has...
- This is a $181,170.00 firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Sartorius Stedim North America Inc., a subsidiary of the German company Sartorius Aktiengesellschaft. The contract is for the provision of Sartorius bioreactor units and accessories. This contract does not have a set-aside designation. Sartorius Stedim North America Inc. is a critical supplier to various federal agencies, providing advanced laboratory equipment, consumables, and...
- The Department of Health and Human Services Food and Drug Administration awarded a $227,968.50 firm fixed price purchase order for service and maintenance on a Sartorius Stedim North America Inc. Ambr 15 bioreactor system. The contract has a completion date of June 30, 2023 and was awarded on a competitive basis with no set-aside designation. Sartorius Stedim North America Inc. is the prime contractor, a division of the German company Sartorius Aktiengesellschaft, and has fulfilled over $2...
- Sartorius Stedim North America, Inc. was awarded a $126,870 purchase order by the Department of Health and Human Services' Food and Drug Administration to provide bioreactor parts and components. As the prime contractor, Sartorius Stedim North America will deliver the requested biomanufacturing equipment components from its Bohemia, New York facility in support of the FDA's regulatory and research programs. The firm fixed price contract runs from August 2023 through September 2024. No set...
- The Department of Health and Human Services Food and Drug Administration has awarded a firm-fixed-price purchase order valued at $211,279.00 to Sartorius Stedim North America Inc., a division of the German company Sartorius Aktiengesellschaft. The contract is for the delivery of the AMBR250 4-WAY MODULAR SYSTEM, which is a bioreactor product used to support the biopharmaceutical manufacturing process. Sartorius Stedim North America Inc. is a leading provider of laboratory equipment, consumables,...
- This is a $210,267.91 firm fixed-price purchase order awarded by the Food and Drug Administration (FDA), a civilian federal agency, to Sartorius Stedim North America Inc., a subsidiary of the German company Sartorius Aktiengesellschaft. The contract is for the delivery of off-line gas analyzers, on-line and integral nutrient analyzers, bioreactor probes, and accessories for a Sartorius BIOSTAT bioreactor system. This award does not have a set-aside designation. Sartorius Stedim North America...
- The Department of Health and Human Services Food and Drug Administration has awarded a firm fixed price purchase order to Sartorius Stedim North America Inc., a division of the German company Sartorius Aktiengesellschaft, to provide an AMBR15 analysis module equipped with BioPAT Spectro hardware and flow cell. The contract has a potential value of $90,507.50 and a completion date of November 17, 2023. No set-aside designation was used for this award. Sartorius Stedim North America Inc. is a...
- This is a firm-fixed-price purchase order awarded by the Plains Area division of an unspecified federal agency to Sartorius Stedim North America Inc., a subsidiary of the German company Sartorius Aktiengesellschaft. The $215,273.00 contract is for the installation and training of large-scale bioreactors, which are essential for efficiently producing biologics in quantities suitable for commercial scale-up operations while maintaining quality. The contract has an ultimate completion date of...
- Sartorius Stedim North America Inc. was awarded a $326,622.90 firm fixed-price purchase order by the U.S. Department of Agriculture's Agricultural Research Services to supply and install a Biostat B bioreactor dual control unit at the National Center for Agricultural Utilization Research (NCAUR) in Bohemia, New York. The contract, awarded on September 6, 2024, with completion by January 4, 2025, fulfills the government's requirement for a dual control unit compatible with existing B. Braun...
The Food and Drug Administration awarded a $86.8K firm fixed-price purchase order to Sartorius Stedim North America Inc. for operational parts and software updates to Biostat B-DCU II bioprocess control units equipped with BioPat analytics systems. The contract, awarded on September 17, 2019, with a completion date of January 30, 2020, represents a non-set-aside procurement for specialized biopharmaceutical manufacturing support equipment. Sartorius Stedim North America Inc., a subsidiary of German multinational Sartorius Aktiengesellschaft, is headquartered in Bohemia, New York, and serves as a critical supplier of advanced laboratory equipment and bioprocess solutions to federal agencies within the Department of Health and Human Services. The Biostat B-DCU II is a widely utilized benchtop bioreactor system in research and biomanufacturing environments, and this procurement ensures continued operational capability through provision of replacement parts and software enhancements for the integrated BioPat analytics platform. Sartorius has established a substantial track record with federal agencies, particularly the FDA, National Institutes of Health, and National Institute of Allergy and Infectious Diseases, providing sophisticated bioprocessing equipment and services that support vaccine development, drug manufacturing, and advanced biological research initiatives. This purchase order reflects FDA's need to maintain and upgrade its existing bioprocess infrastructure in support of its regulatory and research missions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $86.8k | 9/17/19 |